Thank you for your interest in our educational programs.

Should you have any questions about the registration process, please email us at info@diabeteslearningonline.com

BACK About the Program

Be It Resolved That… is an accredited multispecialty educational debate to explore different points of views with regards to a series of complex questions in the management of cardiovascular and renal complications in patient with or without diabetes.


Program Learning Objectives

  • Discuss the cardiorenal protective role of sodium-glucose transport protein 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP1-RA) in patients with and without diabetes.
  • Compare different treatment sequencing options for SGLT2i and GLP1-RA in type 2 diabetes mellitus (T2DM), as well as in chronic kidney disease and heart failure populations with or without type 2 diabetes, based on recently published data.
During this session, the following topics will be discussed:
Topic 1 - Be it resolved that the first agent initiated in all patients with type 2 diabetes should be an SGLT2i/GLP1-RA in place of metformin.

Topic 4 - Be it resolved that in patients with albuminuria, and low-normal blood pressure (with or without T2DM), initiating an SGLT2i over an ACE/ARB will provide more nephroprotection.


April 28th, 2021

Login to Webinar
7:50 pm EDT
Presentation Start
8:00 pm EDT
Closing Remarks
9:30 pm EDT
Add to Calendar 04/28/2021 08:00 pm 04/28/2021 09:30 pm America/Toronto Be It Resolved That...

Thank you for your interest in the webinar presentation of the accredited program titled Be It Resolved That....

Please connect to the platform at 7:50 pm EDT

SPEAKERS:
Alice Cheng, MD, FRCPC

Louis Girard, MD, MBT, FRCPC
MODERATOR: Sara Stafford, MD, FRCPC

WEBINAR CONNECTION: https://www.diabeteslearningonline.com/zoom/?mid=139

Learning Objectives:
Following this program, participants will be able to:
  • Discuss the cardiorenal protective role of sodium-glucose transport protein 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP1-RA) in patients with and without diabetes.
  • Compare different treatment sequencing options for SGLT2i and GLP1-RA in type 2 diabetes mellitus (T2DM), as well as in chronic kidney disease and heart failure populations with or without type 2 diabetes, based on recently published data.
TO JOIN THE MEETING, PLEASE FOLLOW THE STEPS BELOW.
  1. Please download the Zoom application by following the link below:
    https://zoom.us/download

    *If you already have the Zoom application installed, please make sure you are using the latest version of the application.
  2. Instructions to connect to the session:
  3. For audio:
    In the Choose ONE of the audio conference options dialog box, please select one of the following options:
    • RECOMMENDED: connect to the audio using your device microphone and speakers. OR
    • Dial the number 1-855-703-8985 and enter the meeting ID: 933 5670 5145 / password: 090937
    Please note that all lines will be muted. You can communicate with us via the chat box.

    You will need:
    • A computer or tablet.
    • A reliable high‐speed internet connection. To ensure a stable connection, we strongly suggest that the computer you will be using for the presentation is wired to your router.
    For any questions related to this webinar, please contact Melissa Carriere at melissa.carriere@livagency.ca or by phone at 514-209-1484.

    https://www.diabeteslearningonline.com/zoom/?mid=139

Speakers Alice Cheng, MD, FRCPC
Associate Professor, Department of Medicine, University of Toronto
Endocrinologist, Trillium Health Partners in Mississauga and St. Michael’s Hospital
Toronto, ON


Louis Girard, MD, MBT, FRCPC
Clinical Associate Professor and Nephrologist
Medical Director of Apheresis
Medical Director of the Glomerulonephritis Clinic
University of Calgary
Calgary, AB

Moderator Sara Stafford, MD, FRCPC
Endocrinologist







Royal College of Physicians and Surgeons of Canada – Section 1
This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada, approved by Continuing Professional Development, Temerty Faculty of Medicine, University of Toronto for a maximum of 1.5 credits.